Tarsus Pharmaceuticals, Inc. TARS Deferred Tax Assets, Gross
Deferred Tax Assets, Gross at other companies
Other financials
Where this comes from
Reported directly by Tarsus Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:DeferredTaxAssetsGross.
The official record: Tarsus Pharmaceuticals, Inc.’s 10-K, filed February 23, 2026, on SEC EDGAR. View the filing →
Ask your AI about Tarsus Pharmaceuticals, Inc.'s deferred tax assets, gross.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Tarsus Pharmaceuticals, Inc.'s deferred tax assets, gross?
- Tarsus Pharmaceuticals, Inc. (TARS) reported deferred tax assets, gross of $112.67M in Q4 2025.
- How has Tarsus Pharmaceuticals, Inc.'s deferred tax assets, gross changed year-over-year?
- Tarsus Pharmaceuticals, Inc.'s deferred tax assets, gross increased by 27.5% year-over-year, from $88.4M to $112.67M.
- What is the long-term trend for Tarsus Pharmaceuticals, Inc.'s deferred tax assets, gross?
- Over 5 years (2020 to 2025), Tarsus Pharmaceuticals, Inc.'s deferred tax assets, gross has grown at a 71.4% compound annual growth rate (CAGR), from $7.62M to $112.67M.